Literature DB >> 29735391

Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.

Romana Pylypchuk1, Sue Wells1, Andrew Kerr2, Katrina Poppe1, Tania Riddell1, Matire Harwood1, Dan Exeter1, Suneela Mehta1, Corina Grey1, Billy P Wu1, Patricia Metcalf1, Jim Warren3, Jeff Harrison4, Roger Marshall1, Rod Jackson5.   

Abstract

BACKGROUND: Most cardiovascular disease risk prediction equations in use today were derived from cohorts established last century and with participants at higher risk but less socioeconomically and ethnically diverse than patients they are now applied to. We recruited a nationally representative cohort in New Zealand to develop equations relevant to patients in contemporary primary care and compared the performance of these new equations to equations that are recommended in the USA.
METHODS: The PREDICT study automatically recruits participants in routine primary care when general practitioners in New Zealand use PREDICT software to assess their patients' risk profiles for cardiovascular disease, which are prospectively linked to national ICD-coded hospitalisation and mortality databases. The study population included male and female patients in primary care who had no prior cardiovascular disease, renal disease, or congestive heart failure. New equations predicting total cardiovascular disease risk were developed using Cox regression models, which included clinical predictors plus an area-based deprivation index and self-identified ethnicity. Calibration and discrimination performance of the equations were assessed and compared with 2013 American College of Cardiology/American Heart Association Pooled Cohort Equations (PCEs). The additional predictors included in new PREDICT equations were also appended to the PCEs to determine whether they were independent predictors in the equations from the USA.
FINDINGS: Outcome events were derived for 401 752 people aged 30-74 years at the time of their first PREDICT risk assessment between Aug 27, 2002, and Oct 12, 2015, representing about 90% of the eligible population. The mean follow-up was 4·2 years, and a third of participants were followed for 5 years or more. 15 386 (4%) people had cardiovascular disease events (1507 [10%] were fatal, and 8549 [56%] met the PCEs definition of hard atherosclerotic cardiovascular disease) during 1 685 521 person-years follow-up. The median 5-year risk of total cardiovascular disease events predicted by the new equations was 2·3% in women and 3·2% in men. Multivariable adjusted risk increased by about 10% per quintile of socioeconomic deprivation. Māori, Pacific, and Indian patients were at 13-48% higher risk of cardiovascular disease than Europeans, and Chinese or other Asians were at 25-33% lower risk of cardiovascular disease than Europeans. The PCEs overestimated of hard atherosclerotic cardiovascular disease by about 40% in men and by 60% in women, and the additional predictors in the new equations were also independent predictors in the PCEs. The new equations were significantly better than PCEs on all performance metrics.
INTERPRETATION: We constructed a large prospective cohort study representing typical patients in primary care in New Zealand who were recommended for cardiovascular disease risk assessment. Most patients are now at low risk of cardiovascular disease, which explains why the PCEs based mainly on old cohorts substantially overestimate risk. Although the PCEs and many other equations will need to be recalibrated to mitigate overtreatment of the healthy majority, they also need new predictors that include measures of socioeconomic deprivation and multiple ethnicities to identify vulnerable high-risk subpopulations that might otherwise be undertreated. FUNDING: Health Research Council of New Zealand, Heart Foundation of New Zealand, and Healthier Lives National Science Challenge.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29735391     DOI: 10.1016/S0140-6736(18)30664-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  54 in total

1.  Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations.

Authors:  Dennis T Ko; Atul Sivaswamy; Maneesh Sud; Gynter Kotrri; Paymon Azizi; Maria Koh; Peter C Austin; Douglas S Lee; Idan Roifman; George Thanassoulis; Karen Tu; Jacob A Udell; Harindra C Wijeysundera; Todd J Anderson
Journal:  CMAJ       Date:  2020-04-27       Impact factor: 8.262

2.  Increased short-term risk of cardiovascular events in inflammatory rheumatic diseases: results from a population-based cohort.

Authors:  Vital Da Silva Domingues; Ana M Rodrigues; Sara S Dias; Luís Delgado; Ebrahim Barkoudah; Jaime Branco; Helena Canhão
Journal:  Rheumatol Int       Date:  2021-01-03       Impact factor: 2.631

3.  Prediction for the Risk of Multiple Chronic Conditions Among Working Population in the United States With Machine Learning Models.

Authors:  Jingmei Yang; Xinglong Ju; Feng Liu; Onur Asan; Timothy Church; Jeff Smith
Journal:  IEEE Open J Eng Med Biol       Date:  2021-10-06

4.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

Review 5.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

6.  2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Donald E Casey; Randal J Thomas; Vivek Bhalla; Yvonne Commodore-Mensah; Paul A Heidenreich; Dhaval Kolte; Paul Muntner; Sidney C Smith; John A Spertus; John R Windle; Gregory D Wozniak; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-11-26       Impact factor: 24.094

7.  Strategies for prevention of cardiovascular disease in adults with hypertension.

Authors:  Paul K Whelton; Norm R C Campbell; Daniel T Lackland; Gianfranco Parati; C Venkata S Ram; Michael A Weber; Xin-Hua Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

Review 8.  2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Donald E Casey; Randal J Thomas; Vivek Bhalla; Yvonne Commodore-Mensah; Paul A Heidenreich; Dhaval Kolte; Paul Muntner; Sidney C Smith; John A Spertus; John R Windle; Gregory D Wozniak; Boback Ziaeian
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-11-12

9.  Optimizing Atherosclerotic Cardiovascular Disease Risk Estimation for Veterans With Diabetes Mellitus.

Authors:  Sridharan Raghavan; Yuk-Lam Ho; Jason L Vassy; Daniel Posner; Jacqueline Honerlaw; Lauren Costa; Lawrence S Phillips; David R Gagnon; Peter W F Wilson; Kelly Cho
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-08-31

10.  Data Resource: Vascular Risk in Adult New Zealanders (VARIANZ) datasets.

Authors:  S Mehta; R Jackson; D J Exeter; B P Wu; S Wells; A J Kerr
Journal:  Int J Popul Data Sci       Date:  2019-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.